15 Most Successful Penny Stocks in History
Among tens of thousands of penny stocks, only a few made it big, so let’s take a look at 15 most successful penny stocks in history. While most...
Posts Tagged ‘NASDAQ:PCYC’
Pharmacyclics (PCYC), DIRECTV (DTV), Actavis (ACT): Farallon Capital Betting On Merger Arb Plays
Farallon Capital Management, the fund founded by Thomas Steyer in 1986, has filed its 13F for the reporting period of March 31, disclosing an equity...
Pharmacyclics, Inc. (PCYC), Horizon Pharma PLC (HZNP), Auspex Pharmaceuticals Inc (ASPX): Hedge Fund’s Cashing In On Highest Q1 Gainers
The first quarter is up, and our data analytics show that the top three gainers for the quarter were all biotechnology or biopharmaceutical companies...
Baker Bros. Advisors Hits the Jackpot with Pharmacyclics Inc (PCYC) Sale; Incyte Corporation (INCY) Among Fund’s Other Top Picks
Julian Baker and Felix Baker‘s Baker Bros. Advisors’ top pick from the end of 2014 has paid off for the fund in a big way in 2015. AbbVie Inc...
Baker Bros. Advisors Reduces Exposure to MEI Pharma Inc (MEIP) to 3.4%
Julian and Felix Baker‘s Baker Bros. Advisors has decreased its stake in MEI Pharma Inc (NASDAQ:MEIP) to 746,521 shares, from 1,130,317 shares...
Baker Bros. Strengthens Position in Seattle Genetics, Inc. (SGEN)
Julian Baker and Felix Baker have increased their exposure to Seattle Genetics, Inc. (NASDAQ:SGEN) even higher. In a newly amended filing with the SEC...
Hedge Fund News: Bill Miller, Richard Perry & Alphonse Fletcher
Miller: No ‘extraordinary value’ left in US markets (InvestmentWeek) Legg Mason’s Bill Miller is struggling to find the ‘extraordinary...
Sanofi SA (ADR) (SNY), Roche Holding Ltd. (ADR) (RHHBY), GlaxoSmithKline plc (ADR) (GSK): Is the Tide About to Turn in the Fight Against Chronic Lymphocytic Leukemia?
There is perhaps nothing scarier than a cancer diagnosis. A study in 2010 conducted by Cancer Research UK demonstrated this to the “T,” when...
Alexion Pharmaceuticals, Inc. (ALXN), Pharmacyclics, Inc. (PCYC), Aegerion Pharmaceuticals, Inc. (AEGR), Raptor Pharmaceutical Corp. (RPTP): Have These Four Biotechs Peaked?
Biotechnology stocks often trade with excessive valuations, until one day, large losses occur. The best way to protect yourself is to be logical when...
Santarus, Inc. (SNTS), Pharmacyclics, Inc. (PCYC), Ariad Pharmaceuticals, Inc. (ARIA): Should You Jump on This Biotech After Profit-Taking?
After a truly remarkable 20-month 650% gain, shares of Santarus, Inc. (NASDAQ:SNTS) have fallen by more than 20% since its all-time high in early August...
Hedge Funds Are Dumping Dr. Reddy’s Laboratories Limited (ADR) (RDY)
To many of your fellow Dr. Reddy’s Laboratories Limited (ADR) (NYSE:RDY) investors, hedge funds are perceived as overrated, outdated investment...
Is Novo Nordisk A/S (ADR) (NVO) Going to Burn These Hedge Funds?
Should Novo Nordisk A/S (ADR) (NYSE:NVO) investors track the following data? In the 21st century investor’s toolkit, there are a multitude of metrics...
Pharmacyclics, Inc. (PCYC), Johnson & Johnson (JNJ): The FDA Loves This Drug
It should come as no surprise to anyone that the Food and Drug Administration granted a priority review for Pharmacyclics, Inc. (NASDAQ:PCYC) and Johnson...
Johnson & Johnson (JNJ), Pfizer Inc. (PFE), Novartis AG (ADR) (NVS): The Biggest Winners of the FDA’s Breakthrough Designation
Designed as a way to bring potentially life-changing drugs to pharmacy shelves faster than ever, the Food and Drug Administration Safety and Innovation...
Amgen, Inc. (AMGN), Astex Pharmaceuticals, Inc. (ASTX), Pharmacyclics, Inc. (PCYC): This Week in Biotech
With the SPDR S&P Biotech Index up 35% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into...
What Hedge Funds Think About Pharmacyclics, Inc. (PCYC)
In today’s marketplace, there are many metrics market participants can use to track publicly traded companies. A pair of the most innovative are hedge...
Allergan, Inc. (AGN): Hedge Funds Are Bullish and Insiders Are Undecided, What Should You Do?
Is Allergan, Inc. (NYSE:AGN) a buy? In the eyes of many of your fellow readers, hedge funds are seen as useless, old financial vehicles of an era lost...
Forest Laboratories, Inc. (FRX): Hedge Funds Aren’t Crazy About It, Insider Sentiment Unchanged
Is Forest Laboratories, Inc. (NYSE:FRX) a sell? If you were to ask many investors, hedge funds are seen as delayed, old financial tools of an era lost...
Who’s Dumping Teva Pharmaceutical Industries Ltd (ADR) (TEVA)?
Like most pharma companies, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)’s stock price generally trades akin to the actions of a roller...
Pharmacyclics, Inc. (PCYC), Gilead Sciences, Inc. (GILD), Celgene Corporation (CELG): This Small Company Is Winning the War Against Blood Cancer
About 15,680 Americans are diagnosed with chronic lymphocytic leukemia, or CLL, and approximately 5,000 new cases of mantle cell lymphoma, or MCL, occur...
SanDisk Corporation (SNDK), Groupon Inc (GRPN): This Smid Cap-Centered Fund Loves Variety
Bennett Lawrence Management was founded by Van Schreiber in 1995. The hedge fund is primarily focused on small- to mid-cap companies, and prefers growth...
Regeneron Pharmaceuticals Inc (REGN), Pharmacyclics, Inc. (PCYC): Is There Pipeline Potential in These Biotech Stocks?
It is not uncommon for a biotechnology company to be valued solely on the potential of one drug. For many small and midcap biotechs, the potential of...
Pharmacyclics, Inc. (PCYC), Annaly Capital Management, Inc. (NLY): Shorts Are Piling Into These Stocks. Should You Be Worried?
The best thing about the stock market is that you can make money in either direction. Historically, stock indexes have tended to trend up over the long...
Pharmacyclics, Inc. (PCYC) Set to Glide Higher
Pharmacyclics, Inc. (NASDAQ:PCYC) has been a good company to invest in, especially if you had bought shares back in 2009 when it traded around $1 per...
What Does Celgene Corporation (CELG)’s Failed Trial Mean for Investors?
Early this morning, Celgene Corporation (NASDAQ:CELG) announced that it was discontinuing the phase 3 ORIGIN Trial evaluating Revlimid (lenalidomide)...
Can Earnings Push Johnson & Johnson (JNJ) to New Heights?
Johnson & Johnson (NYSE:JNJ) is scheduled to release its quarterly earnings report tomorrow, and as a huge health-care conglomerate with a strong...
Inovio Pharmaceuticals Inc (INO), Alnylam Pharmaceuticals, Inc. (ALNY): This Week in Biotech
With the SPDR S&P Biotech Index up 33% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into the...
Pharmacyclics, Inc. (PCYC): Will This Be the Breakthrough of All Breakthrough Therapy Drugs?
In July 2012, the Food and Drug Administration Safety and Innovation Act was signed into law; and little did we know at the time, but the drug development...
Pharmacyclics, Inc. (PCYC), Johnson & Johnson (JNJ) File for Marketing Approval for Ibrutinib
Pharmacyclics, Inc. (NASDAQ:PCYC) and development partner Janssen, a division of Johnson & Johnson (NYSE:JNJ), announced on Wednesday that a New...
Why Pharmacyclics, Inc. (PCYC) Shares Vaulted Higher
Although we don’t believe in timing the market or panicking over market movements, we do like to keep an eye on big changes — just in case...
Onyx Pharmaceuticals, Inc. (ONXX), Pharmacyclics, Inc. (PCYC): Will This Biotech Acquisition Buzz Lead to More Buyouts?
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) is trading higher after rejecting a takeover bid. As other stocks in its sector also trade higher in sympathy...
Amgen, Inc. (AMGN) Stirs the Pot in the Cancer-Related Sector
Several companies are fighting to be the first to release a treatment or cure for cancer that is a game-changer, and this battle has created a field where...
ACADIA Pharmaceuticals Inc. (ACAD): Look Before You Leap With This Company
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a bio-pharmaceutical company that specializes in the innovation of small-molecule drugs that are used to...
Oncolytics Biotech, Inc. (USA) (ONCY): This High-Risk, High-Reward Biotech Is Worth a Look
Let me preface this by saying that investing in the biotech sector can sometimes be nothing more than speculating. The fortunes of a biotechnology can...
ACADIA Pharmaceuticals Inc. (ACAD) Soars On Hedge Fund Investment
One of the best ways that retail investors can try to decide which stocks will make for a promising investment is to look at what the hedge funds are...
Novo Nordisk A/S (ADR) (NVO): Insiders Aren’t Crazy About It
Novo Nordisk A/S (ADR) (NYSE:NVO) was in 13 hedge funds’ portfolio at the end of the first quarter of 2013. NVO shareholders have witnessed a decrease...
Apple Inc. (AAPL), Alcatel Lucent SA (ADR) (ALU): 4 Stocks On The Verge Of Breaking Out!
Rite Aid Corporation (NYSE:RAD) has been my favorite stock for the better part of the last year. I first began covering the stock when it was at $1.00...
Is Pharmacyclics, Inc. (PCYC) Going to Burn These Hedge Funds?
Is Pharmacyclics, Inc. (NASDAQ:PCYC) an outstanding investment now? Money managers are taking an optimistic view. The number of long hedge fund bets went...
Teva Pharmaceutical Industries Ltd (ADR) (TEVA): Hedge Funds and Insiders Are Bearish, What Should You Do?
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) was in 47 hedge funds’ portfolio at the end of March. TEVA has experienced a decrease in hedge...
Bristol Myers Squibb Co. (BMY), Pharmacyclics, Inc. (PCYC): Hedging Against Leukemia
As I noted 11 weeks ago, cancer statistics are both staggering and disappointing. Although cancer deaths per 100,000 people have been on the downswing...
Corning Incorporated (GLW), Pharmacyclics, Inc. (PCYC), 3D Systems Corporation (DDD): How To Play Them
An analyst upgrade can sometimes be highly useful in allowing you to learn about a new company that might have flown under-the-radar. With the markets...
Sarepta Therapeutics Inc (SRPT), Pharmacyclics, Inc. (PCYC): Are These Billion-Dollar Biotechs Overvalued?
Biotechs with market caps of a billion dollars or more are a dime a dozen. Well, actually, they’re more like $12 billion or more a dozen, but you...
Biogen Idec Inc. (BIIB), Pharmacyclics, Inc. (PCYC), Immunomedics, Inc. (IMMU), and Tackling Cancer, Non-Hodgkin Lymphoma’s Biggest Current & Upcoming Players
As I noted seven weeks ago, cancer statistics are both staggering and disappointing. Although cancer deaths per 100,000 people have been on the downswing...
Pharmacyclics, Inc. (PCYC), Keryx Biopharmaceuticals (KERX): These Cutting-Edge Science Stocks Are Soaring
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you’d like to add some biotech and genome-focused...
Pfizer Inc. (PFE) & More…a ‘Breakthrough’ May Be on the Way for Breast Cancer Patients
The process of developing a drug from start to finish is incredibly arduous, usually involves around $1 billion in costs, and can take upwards of a decade...
Pharmacyclics, Inc. (PCYC), Genomic Health, Inc. (GHDX)…Mega-Hedge Fund Focusing on The Life Sciences
The $3+ billion Baker Brothers Advisors equity portfolio, managed by brothers Julian and Felix Baker, focuses almost exclusively on life science companies...
Johnson & Johnson (JNJ), And Why The FDA’s Latest Designation is More Bling Than Bite
If one “Breakthrough Therapy Designation” is good, three must be great. That is, if we knew what the designation was really worth. Johnson...
Hedge Funds Are Selling Novo Nordisk A/S (ADR) (NYSE:NVO) – Forest Laboratories, Inc. (NYSE:FRX), Dr. Reddy’s Laboratories Limited (ADR) (NYSE:RDY)
Is Novo Nordisk A/S (ADR) (NYSE:NVO) ready to raly soon? Money managers are turning less bullish. The number of long hedge fund positions retreated by...
Pharmacyclics, Inc. (NASDAQ:PCYC): Are Hedge Funds Right About This Stock?
Is Pharmacyclics, Inc. (NASDAQ:PCYC) a healthy stock for your portfolio? Investors who are in the know are becoming hopeful. The number of bullish hedge...
Under-the-Radar Hedge Fund Focusing on Pharmacyclics, Inc. (PCYC), Novadaq Technologies Inc. (NVDQ)
Hedge funds are typically thought of as being billion dollar funds managed by Harvard MBAs and alums of some of Wall Street’s more prestigious analyst...
